Knowledge Hub

Pain Management Therapeutics Market To 2019 - Impact Of Patent Expiries Offset By Demand For Neuropathic And Rheumatoid Pain Medications And Strong Pipeline

Press Release   •   Nov 23, 2016 07:01 EST

The report “Pain Management Therapeutics Market to 2019 Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline“ provides insights and analysis into the market. Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain in a year. Since pain considerably affects day-to-day activities in life, its management presents a considerable challenge for physicians. Inadequate pain control remains a major problem across the world. There is an urgent and unmet need to manage these pain-related problems accurately. Currently, the management of pain is not efficient due to low diagnosis and prescription rates. In many cases, such as cancer pain, 50% of the people taking medicines are not satisfied with the results. This is primarily due to the absence of a perfect pain management solution. Pain management can be most effective only when the underlying disease conditions are cured. However, there is no treatment that offers absolute relief for the indications covered in this report. The medications given for these indications are more for modifying the disease symptoms than offering complete relief from pain. The combination of under-managed pain, low awareness, and fear of addiction to some classes of pain medication is preventing people suffering pain from seeking treatment 100% of the time.


Overview of the pain management market by analyzing the revenue, Annual Cost of Therapy (ACT) and treatment usage pattern across the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan.

Therapeutic landscape of the pain management therapeutics market and includes detailed market sizing and analysis of the trends in eight indications, which are fibromyalgia, neuropathic pain, cancer pain, Osteoarthritis (OA) pain, Rheumatoid Arthritis (RA) pain, migraine, Low Back Pain (LBP) and post-operative pain.

Geographical landscape of the pain management therapeutics market in the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan.

Detailed pipeline analysis of the pain management market (as of April 2013). The section also contains detailed analyses of the most promising pipeline molecules.

Profiles of the top companies operating in the pain management therapeutics market.

List of strategic consolidations, such as M&A deals, licensing agreements and partnership deals that took place in the global pain management therapeutics market between 2007 and 2013.

Download Sample copy of Report at

Reasons to buy

Align your product portfolio to the markets with high growth potential.

Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

Devise a more tailored country strategy through the understanding of key drivers and barriers of the region’s pain management therapeutics market.

Develop key strategic initiatives by understanding the key focus areas and top selling pain management therapeutics molecules of leading companies.

Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 10

1.2 List of Figures 13

2 Pain Management Therapeutics Market to 2019 - Introduction 16

3 Pain Management Therapeutics Market to 2019 - Market Overview 17

3.1 Introduction 17

3.2 World Health Organization Pain Ladder 18

3.3 Risk Evaluation and Mitigation Strategy 19

3.4 Revenue 20

3.5 Major Marketed Pain Management Drugs 21

3.5.1 Abstral (fentanyl citrate) 21

3.5.2 Celebrex (celecoxib) 22

3.5.3 Cymbalta (duloxetine) 23

3.5.4 Exparel (Bupivacaine ER) 24

3.5.5 Lidoderm (lidocaine patch) 25

3.5.6 Lyrica (pregabalin) 26

3.5.7 Nucynta ER (tapentadol ER) 27

3.5.8 Qutenza (capsaicin) 28

3.5.9 Savella (milnacipran hydrochloride) 29

3.5.10 Vimovo (esomeprazole magnesium + naproxen) 30

3.5.11 Voltaren Gel (diclofenac sodium) 31

3.6 Annual Cost of Therapy 32

3.7 Treatment Usage Patterns 33

3.7.1 Prevalence Population 34

3.7.2 Diagnosed Population 34

3.7.3 Prescription Population 34

3.8 Drivers and Restraints of the Pain Management Therapeutics Market 35

3.8.1 Drivers 35

3.8.2 Restraints 36